Status:
TERMINATED
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
Lead Sponsor:
CAMC Health System
Conditions:
Kidney Transplant Immunosuppression
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
Detailed Description
Background: The management of renal transplant recipients is challenging in keeping a delicate balance of immunosuppression to avoid either infection (overimmunosuppression), or rejection (under-immun...
Eligibility Criteria
Inclusion
- De novo kidney transplant patients who are eligible for kidney transplant according to UNOS criteria and agree to participate in the study.
- Patients of both sex aged between 18 to 80 years.
Exclusion
- Any patient with a known immunocompromised disease (e.g. patients with AIDS) or leukocytosis(\>15,000u/L)
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01424345
Start Date
December 1 2011
End Date
July 1 2012
Last Update
October 5 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CAMC
Charleston, West Virginia, United States, 25301